Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

Estimated to cause almost half a million infections per year, the bacterium Clostridioides difficile, also known as C. difficile or "C. diff," can cause diarrhea and inflammation of the large ...

The pharmacologists and toxicologists Prof. Dr. Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the University of Freiburg have identified the molecular docking site that is responsible for ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

A new imaging approach used microscopic glowing tags to reveal gene activity in individual C. diff cells in gut tissue samples from infected mice. Here, a resulting image shows a round cross-section ...

A new study from North Carolina State University shows that the inflammation caused by Clostridioides difficile (C. diff) infection gives the pathogen a two-fold advantage: by both creating an ...

Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.